|
Summary Information: Capricor Therapeutics Inc. Common Stock NASDAQ:CAPR |
  [email protected] |
Our Main Pages Stocks.TRoach.Net TRoach.Org TRoach.Net |
_Description: Capricor Therapeutics, Inc., is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also investigating the field of extracellular vesicles and exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. We are now developing two potential vaccines for COVID-19 as part of our exosome platform.
__The following are links to various summary and news pages for __Capricor Therapeutics Inc. Common Stock [ CAPR ]. __Note: Some Links might not have information for the company. |
|